Sanofi (SNY) Interest Expenses (2009 - 2026)
Sanofi (SNY) posted Interest Expenses of -$333.6 million for Q2 2026, down 60.08% sequentially from -$208.4 million in Q1 2026, and down 527.04% YoY from $78.1 million in Q2 2025.
Sanofi (SNY) Interest Expenses (2009 - 2026) Analysis & Trends
Sanofi has reported Interest Expenses for 18 years, with the latest figure at -$333.6 million in Q2 2026.
- Quarterly Interest Expenses fell 527.04% year-over-year to -$333.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.9 billion (down 10.61% YoY) and the FY2025 annual result came in at $655.4 million, down 42.84% from the prior year.
- Interest Expenses eased to -$333.6 million in Q2 2026 per SNY's latest filing, from -$208.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $893.8 million in Q2 2024 and troughed at -$1.4 billion in Q4 2023.
- A 5-year average of -$317.2 million and a median of -$246.2 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses soared 506.35% in 2024, then plunged 527.04% in 2026.
- Over 5 years, Interest Expenses stood at -$297.9 million in 2022, then tumbled by 366.98% to -$1.4 billion in 2023, then rose by 17.58% to -$1.1 billion in 2024, then surged by 42.84% to -$655.4 million in 2025, then soared by 49.1% to -$333.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$333.6 million, -$208.4 million, and -$655.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -333.60 Mn |
| Jun 30, 2026 | -333.60 Mn |
| Mar 31, 2026 | -208.39 Mn |
| Mar 31, 2026 | -208.39 Mn |
| Dec 31, 2025 | -655.36 Mn |
| Dec 31, 2025 | -655.36 Mn |
| Sep 30, 2025 | -687.40 Mn |
| Sep 30, 2025 | -687.40 Mn |
| Jun 30, 2025 | -53.20 Mn |
| Jun 30, 2025 | -53.20 Mn |
| Mar 31, 2025 | -224.05 Mn |
| Mar 31, 2025 | -224.05 Mn |
| Dec 31, 2024 | -1.15 Bn |
| Dec 31, 2024 | -1.15 Bn |
| Sep 30, 2024 | -280.05 Mn |
| Sep 30, 2024 | -280.05 Mn |
| Jun 30, 2024 | 893.82 Mn |
| Jun 30, 2024 | 893.82 Mn |
| Mar 31, 2024 | -268.33 Mn |
| Mar 31, 2024 | -268.33 Mn |